# A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients

> **NCT00454116** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 106 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Vandetanib
- **DRUG:** FOLFIRI

## Key facts

- **NCT ID:** NCT00454116
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-03
- **Final completion:** 2009-11
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2016-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454116, "A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00454116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*